Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com
by Amy Steele · The Cerbat GemStockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report report published on Monday. The firm issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Price Performance
BLPH opened at $0.04 on Monday. The firm has a market capitalization of $440,388.00, a PE ratio of -0.04 and a beta of 0.70. The business’s 50-day moving average is $0.04 and its two-hundred day moving average is $0.05. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $0.41.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Read More
- Five stocks we like better than Bellerophon Therapeutics
- Market Cap Calculator: How to Calculate Market Cap
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Where to Find Earnings Call Transcripts
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- The Risks of Owning Bonds
- 3 Small-Cap Stocks Ready to Deliver Significant Growth